Consistent with this, treatment of macrophages with the tripeptide toosendanin increased Nrf2 signaling, which attenuated NLRP3 inflammasome activation, decreasing the polarization of macrophages towards the pro-inflammatory (M1) phenotype, thus ameliorating the pathological damages of colitis [46]. The gene discussed is NFE2L2; the disease is colitis.